Skip to Content
  • More Movements at the Top of GSK

    GlaxoSmithKline has been having more than its share of ups and downs over the last few years. In 2014, they moved a lot of assets out of oncology, as part of a… Read More
  • The Drug Project Landscape

    Here’s a new paper in Nature Reviews Drug Discovery that’s going to the trouble of matching specific disease indications with specific mechanisms in… Read More
  • The Latest on China

    China’s impact on biopharma has been a perennial story in the press (and on this blog). The big picture has been the interplay between the “China a… Read More
  • Mongersen Fails

    Readers may recall a post here last year about an odd trial of an antisense drug for Crohn’s disease. Celgene had acquired the drug (mongersen, GED-301)… Read More
  • A Bit About Biopharma Investing

    Well, as predicted here (and many other places), Merck announced yesterday that they are indeed not going to try to seek approval for their CETP inhibitor, anac… Read More
  • It Costs More Than This

    Here’s another paper on the cost to develop a new drug, a topic about which, I’m convinced, debate will never end. This one is designed as a respons… Read More
  • Allergan Pulls A Fast One

    Friday brought news of a drug-company maneuver that I had never heard of, and didn’t even realize was possible. First, a bit of background; the stage need… Read More
Page 2 of 10412345...102030...Last »